US EditionEisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
- E2086 has the potential to improve daytime wakefulness in individuals with narcolepsy type 1, as presented by Eisai.
- The Phase Ib clinical trial evaluated E2086's efficacy, safety, and tolerability against placebo and modafinil in the United States and Canada.
- All doses of E2086 demonstrated statistically significant longer sleep latencies compared to placebo and modafinil, with P<0.0001 for all doses.
- E2086's efficacy and safety findings suggest further investigation is warranted in the narcolepsy patient population.
Insights by Ground AI
Does this summary seem wrong?
65 Articles
65 Articles
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 – DIR HONGKONG
TOKYO, September 8, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. These data demonstrate that once-daily dosing of E2086 has the potential t…
Coverage Details
Total News Sources65
Leaning Left5Leaning Right7Center23Last UpdatedBias Distribution66% Center
Bias Distribution
- 66% of the sources are Center
66% Center
14%
C 66%
R 20%
Factuality
To view factuality data please Upgrade to Premium
